美国国家老龄化研究所和阿尔茨海默病协会阿尔茨海默病研究框架：研究圆桌会议的观点。
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
机构信息
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Biogen, Cambridge, MA, USA.
出版信息
Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.
Abstract
The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the "A, T, N System" (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
摘要
阿尔茨海默病协会研究圆桌会议于 2017 年 11 月召开，旨在探讨新的美国国家老龄化研究所和阿尔茨海默病协会研究框架。会议邀请了学术界、工业界和政府领域的专家就新的美国国家老龄化研究所和阿尔茨海默病协会研究框架提供观点。本综述将总结使用生物标志物的“ A 、 T 、 N 系统”（淀粉样蛋白、 Tau 和神经退行性变），以及如何将其应用于临床研究和药物开发。此外，还将讨论采用这一新框架的潜在挑战和障碍。最后，提出了未来的研究方向。
相似文献
1
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.美国国家老龄化研究所和阿尔茨海默病协会阿尔茨海默病研究框架：研究圆桌会议的观点。
Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.
2
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
3
The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.美国国家老龄化研究所-阿尔茨海默病协会阿尔茨海默病框架：临床试验应用。
Alzheimers Dement. 2019 Jan;15(1):172-178. doi: 10.1016/j.jalz.2018.05.006. Epub 2018 Jun 21.
4
Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.重新审视美国国家老龄化研究所-阿尔茨海默病协会诊断标准的框架。
Alzheimers Dement. 2013 Sep;9(5):594-601. doi: 10.1016/j.jalz.2013.05.1762.
5
National Institute on Aging - Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease.美国国立衰老研究所-阿尔茨海默病协会研究框架为更深入了解阿尔茨海默病奠定了基础。
Alzheimers Dement. 2018 Feb;14(2):261-262. doi: 10.1016/j.jalz.2018.01.001.
6
Common Alzheimer's Disease Research Ontology: National Institute on Aging and Alzheimer's Association collaborative project.常见阿尔茨海默病研究本体：美国国家老龄化研究所和阿尔茨海默病协会合作项目。
Alzheimers Dement. 2012 Jul;8(4):372-5. doi: 10.1016/j.jalz.2012.05.2115.
7
A standard model of Alzheimer's disease?阿尔茨海默病的标准模型？
Prion. 2018;12(5-6):261-265. doi: 10.1080/19336896.2018.1525256. Epub 2018 Oct 9.
8
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.为了定义阿尔茨海默病的临床前阶段：来自美国国家老龄化研究所-阿尔茨海默病协会工作组关于阿尔茨海默病诊断指南的建议。
Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
9
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
10
Alzheimer's disease: The next frontier-Special Report 2017.阿尔茨海默病：下一个前沿领域——2017 年特别报告。
Alzheimers Dement. 2017 Apr;13(4):374-380. doi: 10.1016/j.jalz.2017.02.006. Epub 2017 Mar 14.
引用本文的文献
1
Brain Region-Specific Accumulation of Amyloidosis-Associated Proteins in Postmortem Brain Tissues of Alzheimer's Disease Patients.阿尔茨海默病患者死后脑组织中淀粉样变性相关蛋白的脑区特异性积累。
Mol Neurobiol. 2025 Jul 24. doi: 10.1007/s12035-025-05231-7.
2
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease.开发用于阿尔茨海默病早期风险评估的非侵入性分子标记物。
Biomark Neuropsychiatry. 2025 Jun;12. doi: 10.1016/j.bionps.2025.100120. Epub 2025 Jan 28.
3
Sex Differences in Vulnerability to Tau Pathology: Impact on Cognitive Decline.tau蛋白病变易感性的性别差异：对认知衰退的影响。
medRxiv. 2025 May 26:2025.05.25.25328324. doi: 10.1101/2025.05.25.25328324.
4
Brain Region-specific Accumulation of Amyloidosis-associated Proteins in Postmortem Brain Tissues of Alzheimer's Disease Patients.阿尔茨海默病患者死后脑组织中淀粉样变性相关蛋白的脑区特异性积累
Res Sq. 2025 Jun 3:rs.3.rs-6649354. doi: 10.21203/rs.3.rs-6649354/v1.
5
Advancing dementia preparedness in Low and Middle Income countries: A randomized trial to improve diagnosis in primary care.提高低收入和中等收入国家的痴呆症防治水平：一项改善初级保健诊断的随机试验。
Alzheimers Dement. 2025 May;21(5):e70283. doi: 10.1002/alz.70283.
6
Emerging biophysical origins and pathogenic implications of amyloid oligomers.淀粉样寡聚体新出现的生物物理起源及其致病意义。
Nat Commun. 2025 Mar 26;16(1):2937. doi: 10.1038/s41467-025-58335-y.
7
Retinal Microstructural and Microvascular Changes in Alzheimer Disease: A Review.阿尔茨海默病中的视网膜微观结构和微血管变化：综述
Int Ophthalmol Clin. 2025 Jan 1;65(1):59-67. doi: 10.1097/IIO.0000000000000549. Epub 2024 Dec 23.
8
Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications.阿尔茨海默病的神经炎症生物标志物：从病理生理学到临床意义。
Int J Mol Sci. 2024 Nov 6;25(22):11941. doi: 10.3390/ijms252211941.
9
Guidelines for the use and interpretation of Alzheimer's disease biomarkers in clinical practice in Brazil: recommendations from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.巴西临床实践中阿尔茨海默病生物标志物的使用与解读指南：巴西神经科学院认知神经病学与衰老科学部的建议
Dement Neuropsychol. 2024 Nov 11;18:e2024C001. doi: 10.1590/1980-5764-DN-2024-C001. eCollection 2024.
10
New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.在临床环境中预测迟发性非典型性溶血尿毒综合征（LATE-NC）的新标准：可能/疑似迟发性非典型性溶血尿毒综合征和晚期非典型性溶血尿毒综合征。
J Neuropathol Exp Neurol. 2025 Jan 1;84(1):2-7. doi: 10.1093/jnen/nlae113.
本文引用的文献
1
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.广泛性脑 tau 及其与衰老、Braak 分期和阿尔茨海默病痴呆的关系。
Brain. 2018 Jan 1;141(1):271-287. doi: 10.1093/brain/awx320.
2
Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults.治疗后的甲状腺功能减退症与老年人的脑血管疾病有关，但与阿尔茨海默病的病理无关。
Neurobiol Aging. 2018 Feb;62:64-71. doi: 10.1016/j.neurobiolaging.2017.10.004. Epub 2017 Nov 4.
3
Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.认知正常的老年人对淀粉样蛋白正电子发射断层扫描生物标志物升高结果的理解。
JAMA Neurol. 2018 Jan 1;75(1):44-50. doi: 10.1001/jamaneurol.2017.2954.
4
In vivo staging of regional amyloid deposition.区域淀粉样蛋白沉积的体内分期
Neurology. 2017 Nov 14;89(20):2031-2038. doi: 10.1212/WNL.0000000000004643. Epub 2017 Oct 18.
5
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample.老年样本中的年龄、血管健康与阿尔茨海默病生物标志物
Ann Neurol. 2017 Nov;82(5):706-718. doi: 10.1002/ana.25071. Epub 2017 Oct 26.
6
Distress Associated with Dementia-Related Psychosis and Agitation in Relation to Healthcare Utilization and Costs.与痴呆相关的精神病和激越相关的痛苦与医疗保健利用和成本的关系。
Am J Geriatr Psychiatry. 2017 Oct;25(10):1074-1082. doi: 10.1016/j.jagp.2017.02.025. Epub 2017 May 25.
7
F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.F-AV-1451 与脑脊液 T 蛋白和 P 蛋白作为阿尔茨海默病的生物标志物。
EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.
8
Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms.神经精神症状与认知障碍：理解共病症状的重要性。
J Alzheimers Dis. 2017;59(1):141-153. doi: 10.3233/JAD-170050.
9
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.50-95岁认知未受损个体中脑β淀粉样变性、tau蛋白病和神经退行性变的年龄及性别特异性患病率：一项横断面研究
Lancet Neurol. 2017 Jun;16(6):435-444. doi: 10.1016/S1474-4422(17)30077-7. Epub 2017 Apr 26.
10
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者血浆神经丝轻链与神经退行性变的关联
JAMA Neurol. 2017 May 1;74(5):557-566. doi: 10.1001/jamaneurol.2016.6117.
Zotero 插件